http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 02 Jul 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Press+Releases/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html <p>BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company&apos;s structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OByNC1aU5ikp3vvY7mjRnhUicbqo7cOR4DZUOmh2KunJtPP_KSnHUntZuapKgjlYyCZ7Xo6fL-smpj-Unnc-S4EGGLMeJ59lHAxPHtNwIOU=" rel="nofollow" target="_blank">click here</a>.</p> <p>Management will provide an http://www.streetinsider.com/Globe+Newswire/OnKure+Therapeutics+to+Host+Virtual+KOL+Event+to+Discuss+PI3K%CE%B1+Inhibitor+Medicines%3A+Selectivity+Matters+%26amp%3B+Pan-Mutant+Allosteric+Inhibition+Delivers%2C+on+July+15%2C+2026/26724181.html Thu, 02 Jul 2026 08:00:00 -0400 A.04843521 A.06822034 A.07309385 A.08167664 A.11608963 A.18820864 A.50216637 A.50216955 O.00177802 O.05010326 O.19975149 O.20026344 O.20043539 O.37303036 O.45971719 O.50470896 O.55938090 OKUR